AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2021
Jun 5, 2021
33670_dirs_2021-06-04_098caa33-4a8b-4a4f-b59e-7c7041bbe0c9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-06-03
Reporting Person: Powell Andrew Kenneth William (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-03 | Stock Option (Right to Buy) | $21.90 | A | 12250 | Acquired | 2031-06-02 | Common Stock (12250) | Direct |
| 2021-06-03 | Restricted Stock Units | $ | A | 3356 | Acquired | Common Stock (3356) | Direct |
Footnotes
F1: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
F2: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F4: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.